Can a blast of radiation make immunotherapy work better against kidney cancer?

NCT ID NCT02306954

Ongoing Disease control Sponsor: Providence Health & Services Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding stereotactic body radiation therapy (SBRT) to high-dose Interleukin-2 (IL-2) can improve response rates in people with metastatic renal cell carcinoma. All participants receive IL-2, and half also get two doses of SBRT to a few tumor spots before starting IL-2. The study aims to see if the combination shrinks more tumors than IL-2 alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose Interleukin-2 (IL-2) with or without stereotactic body radiation therapy (SBRT)
What this could lead to: If adding SBRT boosts the response rate, this could become a new treatment option for metastatic kidney cancer.
What could go wrong: This is a mid-stage trial with only 84 participants, so results may not apply broadly. High-dose IL-2 can cause serious side effects, and the added radiation may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA

Contacts and locations

Show contact details

Locations

Portland Providence Medical Center

Portland, Oregon, 97213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.